After TREGZI, the Real Test for Treg Therapy Begins
The FDA’s first clearance of a regulatory T-cell therapy to reduce the risk of chronic graft-versus-host disease extends the treatment goal of allogeneic stem cell transplantation from “winning against cancer” to “rebuilding immune order”; but with limited source information, the magnitude of benefit, eligible populations, and clinical implementation still need to be clarified through review documents and follow-up data.